医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

American Society of Hematology Annual Meeting

REGiMMUNE to Present Results from the Phase 2b Study of RGI-2001 at the 2022 American Society of Hematology Annual Meeting

REGiMMUNE to Present Results from the Phase 2b Study of RGI-2001 at the 2022 American Society of Hematology Annual Meeting

バイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: American Society of Hematology Annual Meeting at the REGiMMUNE to Present Results the Phase 2b Study of RGI

2022年11月07日

PharmaEssentia Announces Pipeline Presentation During Upcoming American Society of Hematology Annual Meeting

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: American Society of Hematology Annual Meeting PharmaEssentia Announces Pipeline Presentation During Upcoming

2021年10月21日

Takeda to Present Broad Range of Clinical Data During 58th American Society of Hematology Annual Meeting

Takeda to Present Broad Range of Clinical Data During 58th American Society of Hematology Annual Meeting

バイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: American Society of Hematology Annual Meeting Takeda to Present Broad Range of Clinical

2016年11月04日

Takeda Announces Abstracts for ADCETRIS® (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma and Ixazomib in Multiple Myeloma to be Presented at 56th American Society of Hematology Annual Meeting

Takeda Announces Abstracts for ADCETRIS® (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma and Ixazomib in Multiple Myeloma to be Presented at 56th American Society of Hematology Annual Meeting

その他ヘルスバイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬遺伝学　 TimeLine: American Society of Hematology Annual Meeting Brentuximab Vedotin Cell Lymphoma and Ixazomib in Multiple Myeloma Systemic Anaplastic Large Takeda Announces Abstracts for ADCETRIS

2014年11月07日

Takeda Announces More than 370 Abstracts on VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and Leading Pipeline Compounds to be Presented at 55th American Society of Hematology Annual Meeting

Takeda Announces More than 370 Abstracts on VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and Leading Pipeline Compounds to be Presented at 55th American Society of Hematology Annual Meeting

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: American Society of Hematology Annual Meeting Brentuximab Vedotin Pipeline Compounds to be Presented at 55th Takeda Announces More than 370 Abstracts on

2013年11月12日